Actinic Keratosis Treatment Market

Actinic Keratosis Treatment Market

  • HC-1253
  • 4.7 Rating
  • 190 Pages
  • Upcoming
  • 70 Reviews
  • PDF Excel PPT
raksha

Author :

Raksha Sharma

Vineet

Fact-checked by :

Vineet Pandey

Vishal

Editor :

Vishal Golekar

Actinic Keratosis Treatment Market Outlook 2032

The global actinic keratosis treatment market size was USD 6.8 Billion in 2023 and is projected to reach USD 10.3 Billion by 2032, expanding at a CAGR of 4.8% during 2024–2032. The market growth is attributed to the high demand for non-invasive actinic keratosis treatment.

Growing number of fair skin and older age population suffering from actinic keratosis lesions are resulting in high demand for AK treatment, which further boosts the market. Individuals with fair skin types, particularly those with Fitzpatrick skin types I and II, are at increased risk of developing AK lesions due to reduced melanin protection against UV radiation. Furthermore, growing awareness about sun protection measures and skin cancer prevention initiatives further boost the market in the coming years.

  • According to the report published by The Skin Cancer Foundation in February 2024, more than 419,000 cases of skin cancer in the U.S. each year are attributed to indoor tanning.

Actinic Keratosis Treatment Market Outlook

Impact of Artificial Intelligence (AI) in Actinic Keratosis Treatment Market

The use of artificial intelligence is likely to boost the actinic keratosis treatment market. AI-powered image recognition systems help to analyze dermoscopic images of AK lesions for early detection and characterization of suspicious lesions. Moreover, AI-driven decision support tools assist healthcare providers in selecting the most appropriate treatment regimens based on lesion characteristics and patient demographics.

Actinic Keratosis Treatment Market Dynamics

Actinic Keratosis Treatment Market Dynamics

Major Drivers

Increasing incidence of actinic keratosis (AK) lesions is anticipated to drive the market. Factors, such as prolonged sun exposure, aging population, and increasing awareness about skin cancer risks are creating demand for AK treatments. For instance, according to the report published by Almirall, S.A, a leading pharmaceutical company on May 24, 2023, their survey in the EU and US reveals limited knowledge about this skin condition, which affects 13.3% of the European population. Additionally, the growing emphasis on preventive dermatological care and routine skin examinations further boosts the market.

Existing Restraints

Limited efficacy of existing treatments for Actinic Keratosis (AK) is expected to hinder the market. The effectiveness of various treatment options available, including topical therapies, cryotherapy, and photodynamic therapy is low in completely eliminating AK lesions. Additionally, the potential side effects associated with certain treatment modalities, such as skin irritation, blistering, and scarring, deter some patients from seeking treatment, thereby hampering the market.

Emerging Opportunities

­Rising investments in research and development (R&D) of novel actinic keratosis (AK) treatments are anticipated to create immense opportunities for the players competing in the market. Pharmaceutical companies are increasingly focusing on developing innovative therapies with improved efficacy, safety profiles, and patient outcomes. Novel treatment modalities under investigation, include immune response modifiers, personalized medicine, and gene-based interventions to address unmet needs in AK management. Additionally, advancements in drug delivery technologies, such as nanoparticle formulations and microneedle patches, enable targeted drug delivery and enhanced skin penetration, enhancing the therapeutic efficacy of AK medications. These all factors further contribute to fueling the market in the coming years.

Scope of the Actinic Keratosis Treatment Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Attributes

Details

Report Title

Actinic Keratosis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2023

Historic Data

2017 -2022

Forecast Period

2024–2032

Segmentation

Therapy (Surgery, Topical, and Photodynamic Therapy), Drug Class (NSAID, Nucleoside Metabolic Inhibitor, Immune Response Modifiers, Photoenhancers, and Others), and End-user (Private Clinics, Hospitals, Homecare, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast

Key Players Covered in the Report

Almirall S.A.; Bausch Health Companies Inc; BIOFRONTERA AG; GALDERMA; LEO Pharma A/S; Novartis AG; and Sun Pharmaceutical Industries Ltd


Regional Outlook

In terms of region, the global actinic keratosis treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023, due to the well-established healthcare infrastructure, and increasing adoption of advanced treatment modalities. Furthermore, the high prevalence of AK in this region further boosts the market in the coming years.

  • As per the report published by the American Academy of Dermatology Association, it is estimated that more than 40 million Americans develop actinic keratoses (AKs) each year.

The market in Europe is projected to grow at a significant pace in the years to come, owing to the increasing healthcare expenditure and advancements in diagnostic and treatment technologies. Additionally, favorable regulatory policies and reimbursement frameworks for dermatological treatments further fuel the market during the forecast period.

Actinic Keratosis Treatment Market Region

Actinic Keratosis Treatment Market Segment Insights

Therapy Segment Analysis

Based on therapy, the actinic keratosis treatment market is divided into surgery, topical, and photodynamic therapy. The photodynamic segment is expected to expand at a significant growth rate in the coming years, owing to the advancements in PDT technology for superior cosmetic outcomes compared to traditional therapies.

PDT offers targeted lesion destruction and reduced risk of recurrence which makes it an attractive option for both patients and healthcare providers. Moreover, the growing adoption of combination therapies incorporating PDT with other treatment modalities, such as topical medications or cryotherapy, further enhances its efficacy and fuels the segment.
 

Actinic Keratosis Treatment Market Therapies

Drug Class Segment Analysis

On the basis of drug class, the global market is segregated into NSAID, nucleoside metabolic inhibitor, immune response modifiers, photoenhancers, and others. The immune response modifiers segment held largest market share in 2023, due to their convenient application and relatively low incidence of adverse effects compared to other drug classes.

IRMs, such as imiquimod and ingenol mebutate offer a non-invasive treatment option with favorable cosmetic outcomes. Moreover, the growing body of clinical evidence supporting the efficacy of IRMs in AK management further boosts their demand.

The photoenhancers segment is anticipated to grow at a substantial CAGR during the forecast period, owing to their superior lesion clearance rates compared to traditional PDT. Additionally, the growing adoption of combination therapies incorporating photoenhancers with topical medications or cryotherapy, further enhances their efficacy and proples the segment.

Actinic Keratosis Treatment Market Drug Class

End-user Segment Analysis

Based on end-user, the actinic keratosis treatment market is segmented into private clinics, hospitals, homecare, and others. The homecare segment is projected to register a robust growth rate during the assessment years, due to the changing patient preferences for remote healthcare services. Homecare services are convenient and flexible for patients requiring long-term AK management. Moreover, the growing availability of homecare devices and self-administered treatment options, such as topical medications and photodynamic therapy (PDT) kits further boosts the segment.

Segments

Therapies

  • Topical
  • Surgery
  • Photodynamic Therapy

Drug Classes

  • Nucleoside Metabolic Inhibitors
  • NSAIDs
  • Immune Response Modifiers
  • Photoenhancers
  • Others

End-Users

  • Hospitals
  • Private Clinics
  • Homecare
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

Competitive Landscape

Key players competing in the global actinic keratosis treatment market are Almirall S.A.; Bausch Health Companies Inc; BIOFRONTERA AG; GALDERMA; LEO Pharma A/S; Novartis AG; and Sun Pharmaceutical Industries Ltd.

These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base worldwide. For instance,

  • On September 27, 2021, Almirall, S.A., a pharmaceutical company, announced the official release of Klisyri (tirbanibulin), an innovative treatment for actinic keratosis, in Germany and the UK. The European Commission and the UK Medicines & Healthcare Products Regulatory Agency (MHRA) approved it in July and August 2021, respectively, for the topical treatment of actinic keratosis (AK) on the face and scalp in adults.

Actinic Keratosis Treatment Market Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Actinic Keratosis Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Actinic Keratosis Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Actinic Keratosis Treatment Market - Supply Chain
  4.5. Global Actinic Keratosis Treatment Market Forecast
     4.5.1. Actinic Keratosis Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Actinic Keratosis Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Actinic Keratosis Treatment Market Absolute $ Opportunity
5. Global Actinic Keratosis Treatment Market Analysis and Forecast by End Users
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by End Users
     5.2.2. Y-o-Y Growth Projections by End Users
  5.3. Actinic Keratosis Treatment Market Size and Volume Forecast by End Users
     5.3.1. Hospitals
     5.3.2. Private Clinics
     5.3.3. Homecare
     5.3.4. Others
  5.4. Absolute $ Opportunity Assessment by End Users
  5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Actinic Keratosis Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Actinic Keratosis Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Actinic Keratosis Treatment Demand Share Forecast, 2019-2026
7. North America Actinic Keratosis Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Actinic Keratosis Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Actinic Keratosis Treatment Market Size and Volume Forecast by End Users
     7.4.1. Hospitals
     7.4.2. Private Clinics
     7.4.3. Homecare
     7.4.4. Others
  7.5. Basis Point Share (BPS) Analysis by End Users
  7.6. Y-o-Y Growth Projections by End Users
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Actinic Keratosis Treatment Demand Share Forecast, 2019-2026
8. Latin America Actinic Keratosis Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Actinic Keratosis Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Actinic Keratosis Treatment Market Size and Volume Forecast by End Users
     8.4.1. Hospitals
     8.4.2. Private Clinics
     8.4.3. Homecare
     8.4.4. Others
  8.5. Basis Point Share (BPS) Analysis by End Users
  8.6. Y-o-Y Growth Projections by End Users
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Actinic Keratosis Treatment Demand Share Forecast, 2019-2026
9. Europe Actinic Keratosis Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Actinic Keratosis Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Actinic Keratosis Treatment Market Size and Volume Forecast by End Users
     9.4.1. Hospitals
     9.4.2. Private Clinics
     9.4.3. Homecare
     9.4.4. Others
  9.5. Basis Point Share (BPS) Analysis by End Users
  9.6. Y-o-Y Growth Projections by End Users
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Actinic Keratosis Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Actinic Keratosis Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Actinic Keratosis Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Actinic Keratosis Treatment Market Size and Volume Forecast by End Users
     10.4.1. Hospitals
     10.4.2. Private Clinics
     10.4.3. Homecare
     10.4.4. Others
  10.5. Basis Point Share (BPS) Analysis by End Users
  10.6. Y-o-Y Growth Projections by End Users
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Actinic Keratosis Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Actinic Keratosis Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Actinic Keratosis Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Actinic Keratosis Treatment Market Size and Volume Forecast by End Users
     11.4.1. Hospitals
     11.4.2. Private Clinics
     11.4.3. Homecare
     11.4.4. Others
  11.5. Basis Point Share (BPS) Analysis by End Users
  11.6. Y-o-Y Growth Projections by End Users
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Actinic Keratosis Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Actinic Keratosis Treatment Market: Market Share Analysis
  12.2. Actinic Keratosis Treatment Distributors and Customers
  12.3. Actinic Keratosis Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Almirall S.A.
     12.4.2. Bausch Health Companies Inc
     12.4.3. BIOFRONTERA AG
     12.4.4. GALDERMA
     12.4.5. LEO Pharma A/S
     12.4.6. Novartis AG
     12.4.7. Sun Pharmaceutical Industries Ltd

Purchase Premium Report